Rituximab Helps Ease Disability in Children With NMOSD, Study Finds

Rituximab may be effective for improving functionality in children with neuromyelitis optica spectrum disorder (NMOSD) or other inflammatory neurological disorders, though more research is needed to identify optimal treatment regimens, a new study reports. “Efficacy of [rituximab] in specific indications and good tolerance are confirmed in pediatric neurology.

Movement in the Recovery From Transverse Myelitis

“Can you walk down the hall for me, please?” My specialist, with a stern look on her face, waits patiently. “And back again toward me now.” It feels so ridiculous that, as a 40-year-old woman, I’m being asked to do this. I steady myself and walk down the hallway. I…

Why We Discuss Disability With Our Young Child

In my family, I am the third child of four, the daughter of proud, immigrant parents. I grew up in small towns until I finally relocated to Toronto in my early 20s. Growing up, I only knew one kid with an illness, and she entered my life as quickly as…

Uplizna Reduced Disability Progression in Patients During Trial

Treatment with Uplizna (inebilizumab-cdon) can reduce disability progression in people with neuromyelitis optica spectrum disorder (NMOSD), findings from the N-MOmentum clinical trial show. The results were published in Neurology Neuroimmunology & Neuroinflammation, in a study, “Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis…